BMC health services research
An updated cost-effectiveness analysis of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer: the perspective of the United States.
Fangping Chen, Xiaowei Xu, Xiaocong Wang
Published: 202610.1186/s12913-025-13958-1
No abstract available for this study.